In fact, MAO-B inhibitors have been proposed as biomarkers for astrocytosis in neurodegenerative diseases associated with cell death or the activation of immune responses, with some investigations reporting higher MAO-B binding in Alzheimer’s disease patients versus aged-matched controls [8,9]. Here, MAOB is linked to neurodegenerative disease.